Table of Contents
Journal of Signal Transduction
Volume 2012, Article ID 123253, 14 pages
http://dx.doi.org/10.1155/2012/123253
Review Article

NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases

1Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada T6G 2E1
2Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada T6G 2B7

Received 21 March 2012; Accepted 28 April 2012

Academic Editor: Rudi Beyaert

Copyright © 2012 Joel D. Pearson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Pulford, L. Lamant, S. W. Morris et al., “Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1,” Blood, vol. 89, no. 4, pp. 1394–1404, 1997. View at Google Scholar · View at Scopus
  2. T. Iwahara, J. Fujimoto, D. Wen et al., “Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system,” Oncogene, vol. 14, no. 4, pp. 439–449, 1997. View at Google Scholar · View at Scopus
  3. S. W. Morris, C. Naeve, P. Mathew et al., “ALK the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK),” Oncogene, vol. 14, no. 18, pp. 2175–2188, 1997. View at Google Scholar · View at Scopus
  4. E. Vernersson, N. K. S. Khoo, M. L. Henriksson, G. Roos, R. H. Palmer, and B. Hallberg, “Characterization of the expression of the ALK receptor tyrosine kinase in mice,” Gene Expression Patterns, vol. 6, no. 5, pp. 448–461, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. R. H. Palmer, E. Vernersson, C. Grabbe, and B. Hallberg, “Anaplastic lymphoma kinase: signalling in development and disease,” Biochemical Journal, vol. 420, no. 3, pp. 345–361, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. J. B. Weiss, C. Xue, T. Benice, L. Xue, S. W. Morris, and J. Raber, “Anaplastic lymphoma kinase and leukocyte tyrosine kinase: functions and genetic interactions in learning, memory and adult neurogenesis,” Pharmacology, Biochemistry, and Behavior, vol. 100, no. 3, pp. 566–574, 2012. View at Google Scholar
  7. J. G. Bilsland, A. Wheeldon, A. Mead et al., “Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications,” Neuropsychopharmacology, vol. 33, no. 3, pp. 685–700, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. A. W. Lasek, J. Lim, C. L. Kliethermes et al., “An evolutionary conserved role for anaplastic lymphoma kinase in behavioral responses to ethanol,” PLoS ONE, vol. 6, no. 7, Article ID e22636, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Kunugi, R. Hashimoto, T. Okada et al., “Possible association between nonsynonymous polymorphisms of the anaplastic lymphoma kinase (ALK) gene and schizophrenia in a Japanese population,” Journal of Neural Transmission, vol. 113, no. 10, pp. 1569–1573, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Englund, C. E. Lorén, C. Grabbe et al., “Jeb signals through the Alk receptor tyrosine kinase to drive visceral muscle fusion,” Nature, vol. 425, no. 6957, pp. 512–516, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. H. H. Lee, A. Norris, J. B. Weiss, and M. Frasch, “Jelly belly protein activates the receptor tyrosine kinase Alk to specify visceral muscle pioneers,” Nature, vol. 425, no. 6957, pp. 507–512, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Stute, K. Schimmelpfeng, R. Renkawitz-Pohl, R. H. Palmer, and A. Holz, “Myoblast determination in the somatic and visceral mesoderm depends on Notch signalling as well as on milliways (miliAlk) as receptor for jeb signalling,” Development, vol. 131, no. 4, pp. 743–754, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. G. E. Stoica, A. Kuo, A. Aigner et al., “Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin,” Journal of Biological Chemistry, vol. 276, no. 20, pp. 16772–16779, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. G. E. Stoica, A. Kuo, C. Powers et al., “Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types,” Journal of Biological Chemistry, vol. 277, no. 39, pp. 35990–35998, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Moog-Lutz, J. Degoutin, J. Y. Gouzi et al., “Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin,” Journal of Biological Chemistry, vol. 280, no. 28, pp. 26039–26048, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Motegi, J. Fujimoto, M. Kotani, H. Sakuraba, and T. Yamamoto, “ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth,” Journal of Cell Science, vol. 117, no. 15, pp. 3319–3329, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Perez-Pinera, W. Zhang, Y. Chang, J. A. Vega, and T. F. Deuel, “Anaplastic lymphoma kinase is activated through the pleiotrophin/receptor protein-tyrosine phosphatase β/ζ signaling pathway: an alternative mechanism of receptor tyrosine kinase activation,” Journal of Biological Chemistry, vol. 282, no. 39, pp. 28683–28690, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Mourali, A. Bénard, F. C. Lourenço et al., “Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage,” Molecular and Cellular Biology, vol. 26, no. 16, pp. 6209–6222, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Mehlen and D. E. Bredesen, “The dependence receptor hypothesis,” Apoptosis, vol. 9, no. 1, pp. 37–49, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. S. W. Morris, M. N. Kirstein, M. B. Valentine et al., “Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma,” Science, vol. 263, no. 5151, pp. 1281–1284, 1994. View at Google Scholar · View at Scopus
  21. M. Shiota, J. Fujimoto, T. Semba, H. Satoh, T. Yamamoto, and S. Mori, “Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3,” Oncogene, vol. 9, no. 6, pp. 1567–1574, 1994. View at Google Scholar · View at Scopus
  22. D. A. Arber, L. H. Sun, and L. M. Weiss, “Detection of the t(2;5)(p23;q35) chromosomal translocation in large B- cell lymphomas other than anaplastic large cell lymphoma,” Human Pathology, vol. 27, no. 6, pp. 590–594, 1996. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Lamant, N. Dastugue, K. Pulford, G. Delsol, and B. Mariamé, “A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation,” Blood, vol. 93, no. 9, pp. 3088–3095, 1999. View at Google Scholar · View at Scopus
  24. R. Siebert, S. Gesk, L. Harder et al., “Complex variant translocation t(1;2) with TPM3-ALK fusion due to cryptic ALK gene rearrangement in anaplastic large-cell lymphoma,” Blood, vol. 94, no. 10, pp. 3614–3617, 1999. View at Google Scholar · View at Scopus
  25. B. Lawrence, A. Perez-Atayde, M. K. Hibbard et al., “TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors,” American Journal of Pathology, vol. 157, no. 2, pp. 377–384, 2000. View at Google Scholar · View at Scopus
  26. E. Sugawara, Y. Togashi, N. Kuroda et al., “Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method,” Cancer. In press.
  27. L. Hernández, M. Pinyol, S. Hernández et al., “TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations,” Blood, vol. 94, no. 9, pp. 3265–3268, 1999. View at Google Scholar · View at Scopus
  28. K. Rikova, A. Guo, Q. Zeng et al., “Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer,” Cell, vol. 131, no. 6, pp. 1190–1203, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Trinei, L. Lanfrancone, E. Campo et al., “A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma,” Cancer Research, vol. 60, no. 4, pp. 793–798, 2000. View at Google Scholar · View at Scopus
  30. Z. Ma, J. Cools, P. Marynen et al., “Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis,” Blood, vol. 95, no. 6, pp. 2144–2149, 2000. View at Google Scholar · View at Scopus
  31. G. W. B. Colleoni, J. A. Bridge, B. Garicochea, J. Liu, D. A. Filippa, and M. Ladanyi, “ATIC-ALK: a novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35),” American Journal of Pathology, vol. 156, no. 3, pp. 781–789, 2000. View at Google Scholar · View at Scopus
  32. M. Debiec-Rychter, P. Marynen, A. Hagemeijer, and P. Pauwels, “ALK-ATIC fusion in urinary bladder inflammatory myofibroblastic tumor,” Genes Chromosomes and Cancer, vol. 38, no. 2, pp. 187–190, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. C. Touriol, C. Greenland, L. Lamant et al., “Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like),” Blood, vol. 95, no. 10, pp. 3204–3207, 2000. View at Google Scholar · View at Scopus
  34. J. A. Bridge, M. Kanamori, Z. Ma et al., “Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor,” American Journal of Pathology, vol. 159, no. 2, pp. 411–415, 2001. View at Google Scholar · View at Scopus
  35. P. De Paepe, M. Baens, H. van Krieken et al., “ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma,” Blood, vol. 102, no. 7, pp. 2638–2641, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. R. D. Gascoyne, L. Lamant, J. I. Martin-Subero et al., “ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases,” Blood, vol. 102, no. 7, pp. 2568–2573, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. N. Chikatsu, H. Kojima, K. Suzukawa et al., “ALK+, CD30-, CD20- large B-cell lymphoma containing anaplastic lymphoma kinase (ALK) fused to clathrin heavy chain gene (CLTC),” Modern Pathology, vol. 16, no. 8, pp. 828–832, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. W. Y. Wang, L. Gu, W. P. Liu, G. D. Li, H. J. Liu, and Z. G. Ma, “ALK-positive extramedullary plasmacytoma with expression of the CLTC-ALK fusion transcript,” Pathology, Research and Practice, vol. 207, no. 9, pp. 587–591, 2011. View at Google Scholar
  39. S. J. Meech, L. McGavran, L. F. Odom et al., “Unusual childhood extramedullary hematologic malignancy with natural killer cell properties that contains tropomyosin 4—anaplastic lymphoma kinase gene fusion,” Blood, vol. 98, no. 4, pp. 1209–1216, 2001. View at Publisher · View at Google Scholar · View at Scopus
  40. F. R. Jazii, Z. Najafi, R. Malekzadeh et al., “Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer,” World Journal of Gastroenterology, vol. 12, no. 44, pp. 7104–7112, 2006. View at Google Scholar · View at Scopus
  41. X. L. Du, H. Hu, D. C. Lin et al., “Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma,” Journal of Molecular Medicine, vol. 85, no. 8, pp. 863–875, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. F. Tort, M. Pinyol, K. Pulford et al., “Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma,” Laboratory Investigation, vol. 81, no. 3, pp. 419–426, 2001. View at Google Scholar · View at Scopus
  43. J. Cools, I. Wlodarska, R. Somers et al., “Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor,” Genes Chromosomes and Cancer, vol. 34, no. 4, pp. 354–362, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. Z. Ma, D. A. Hill, M. H. Collins et al., “Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor,” Genes Chromosomes and Cancer, vol. 37, no. 1, pp. 98–105, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. L. Lamant, R. D. Gascoyne, M. M. Duplantier et al., “Non-muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma,” Genes Chromosomes and Cancer, vol. 37, no. 4, pp. 427–432, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. I. Panagopoulos, T. Nilsson, H. A. Domanski et al., “Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor,” International Journal of Cancer, vol. 118, no. 5, pp. 1181–1186, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. K. Van Roosbroeck, J. Cools, D. Dierickx et al., “ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions,” Haematologica, vol. 95, no. 3, pp. 509–513, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. C. Bedwell, D. Rowe, D. Moulton, G. Jones, N. Bown, and C. M. Bacon, “Cytogenetically complex SEC31A-ALK fusions are recurrent in ALK-positive large B-cell lymphomas,” Haematologica, vol. 96, no. 2, pp. 343–346, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Soda, Y. L. Choi, M. Enomoto et al., “Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer,” Nature, vol. 448, no. 7153, pp. 561–566, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. E. Lin, L. Li, Y. Guan et al., “Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers,” Molecular Cancer Research, vol. 7, no. 9, pp. 1466–1476, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. K. Takeuchi, M. Soda, Y. Togashi et al., “Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma,” Haematologica, vol. 96, no. 3, pp. 464–467, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. L. V. Debelenko, S. C. Raimondi, N. Daw et al., “Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum,” Modern Pathology, vol. 24, no. 3, pp. 430–442, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Mariño-Enríquez, W. B. Ou, C. B. Weldon, J. A. Fletcher, and A. R. Pérez-Atayde, “ALK rearrangement in sickle cell trait-associated renal medullary carcinoma,” Genes Chromosomes and Cancer, vol. 50, no. 3, pp. 146–153, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. K. Takeuchi, L. C. Young, Y. Togashi et al., “KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer,” Clinical Cancer Research, vol. 15, no. 9, pp. 3143–3149, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. K. Takeuchi, M. Soda, Y. Togashi et al., “Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification,” Clinical Cancer Research, vol. 17, no. 10, pp. 3341–3348, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. D. Lipson, M. Capelletti, R. Yelensky et al., “Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies,” Nature Medicine, vol. 18, no. 3, pp. 382–384, 2012. View at Google Scholar
  57. Y. Togashi, M. Soda, S. Sakata et al., “KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only,” PLoS ONE, vol. 7, no. 2, Article ID e31323, 2012. View at Google Scholar
  58. G. Delsol, B. Falini, H. K. Muller-Hermelink et al., Anaplastic Large Cell Lymphoma (ALCL), ALK-Positive, International Agency for Research on Cancer (IARC), Lyon, France, 4th edition, 2008.
  59. A. Fornari, R. Piva, R. Chiarle, D. Novero, and G. Inghirami, “Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma?” Hematological Oncology, vol. 27, no. 4, pp. 161–170, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. P. Fischer, E. Nacheva, D. Y. Mason et al., “A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor β-chain gene,” Blood, vol. 72, no. 1, pp. 234–240, 1988. View at Google Scholar · View at Scopus
  61. R. Rimokh, J. P. Magaud, F. Berger et al., “A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma (Ki-1 lymphoma),” British Journal of Haematology, vol. 71, no. 1, pp. 31–36, 1989. View at Google Scholar · View at Scopus
  62. Y. Kaneko, G. Frizzera, S. Edamura et al., “A novel translocation, t(2;5)(p23;q35), in childhood phagocytic large T-cell lymphoma mimicking malignant histiocytosis,” Blood, vol. 73, no. 3, pp. 806–813, 1989. View at Google Scholar · View at Scopus
  63. D. Y. Mason, C. Bastard, R. Rimokh et al., “CD30-positive large cell lymphomas (Ki-1 lymphoma) are associated with a chromosomal translocation involving 5q35,” British Journal of Haematology, vol. 74, no. 2, pp. 161–168, 1990. View at Google Scholar · View at Scopus
  64. M. M. Le Beau, M. A. Bitter, R. A. Larson et al., “The t(2;5)(p23;q35): a recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma,” Leukemia, vol. 3, no. 12, pp. 866–870, 1989. View at Google Scholar · View at Scopus
  65. C. A. Griffin, A. L. Hawkins, C. Dvorak, C. Henkle, T. Ellingham, and E. J. Perlman, “Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors,” Cancer Research, vol. 59, no. 12, pp. 2776–2780, 1999. View at Google Scholar · View at Scopus
  66. C. Gambacorti-Passerini, C. Messa, and E. M. Pogliani, “Crizotinib in anaplastic large-cell lymphoma,” The New England Journal of Medicine, vol. 364, no. 8, pp. 775–776, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. E. L. Kwak, Y. J. Bang, D. R. Camidge et al., “Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer,” The New England Journal of Medicine, vol. 363, no. 18, pp. 1693–1703, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. J. E. Butrynski, D. R. D'Adamo, J. L. Hornick et al., “Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor,” The New England Journal of Medicine, vol. 363, no. 18, pp. 1727–1733, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. P. Perez-Pinera, Y. Chang, A. Astudillo, J. Mortimer, and T. F. Deuel, “Anaplastic lymphoma kinase is expressed in different subtypes of human breast cancer,” Biochemical and Biophysical Research Communications, vol. 358, no. 2, pp. 399–403, 2007. View at Publisher · View at Google Scholar · View at Scopus
  70. L. Lamant, K. Pulford, D. Bischof et al., “Expression of the ALK tyrosine kinase gene in neuroblastoma,” American Journal of Pathology, vol. 156, no. 5, pp. 1711–1721, 2000. View at Google Scholar · View at Scopus
  71. I. Janoueix-Lerosey, D. Lequin, L. Brugières et al., “Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma,” Nature, vol. 455, no. 7215, pp. 967–970, 2008. View at Publisher · View at Google Scholar · View at Scopus
  72. Y. Chen, J. Takita, Y. L. Choi et al., “Oncogenic mutations of ALK kinase in neuroblastoma,” Nature, vol. 455, no. 7215, pp. 971–974, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. R. E. George, T. Sanda, M. Hanna et al., “Activating mutations in ALK provide a therapeutic target in neuroblastoma,” Nature, vol. 455, no. 7215, pp. 975–978, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. H. Carén, F. Abel, P. Kogner, and T. Martinsson, “High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours,” Biochemical Journal, vol. 416, no. 2, pp. 153–159, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. Y. P. Mossé, M. Laudenslager, L. Longo et al., “Identification of ALK as a major familial neuroblastoma predisposition gene,” Nature, vol. 455, no. 7215, pp. 930–935, 2008. View at Publisher · View at Google Scholar · View at Scopus
  76. A. K. Murugan and M. M. Xing, “Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene,” Cancer Research, vol. 71, no. 13, pp. 4403–4411, 2011. View at Publisher · View at Google Scholar · View at Scopus
  77. D. Wang, H. Umekawa, and M. O. J. Olson, “Expression and subcellular locations of two forms of nucleolar protein B23 in rat tissues and cells,” Cellular and Molecular Biology Research, vol. 39, no. 1, pp. 33–42, 1993. View at Google Scholar · View at Scopus
  78. R. A. Borer, C. F. Lehner, H. M. Eppenberger, and E. A. Nigg, “Major nucleolar proteins shuttle between nucleus and cytoplasm,” Cell, vol. 56, no. 3, pp. 379–390, 1989. View at Google Scholar · View at Scopus
  79. E. Colombo, M. Alcalay, and P. G. Pelicci, “Nucleophosmin and its complex network: a possible therapeutic target in hematological diseases,” Oncogene, vol. 30, no. 23, pp. 2595–2609, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. J. Fujimoto, M. Shiota, T. Iwahara et al., “Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5),” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 9, pp. 4181–4186, 1996. View at Publisher · View at Google Scholar · View at Scopus
  81. D. Bischof, K. Pulford, D. Y. Mason, and S. W. Morris, “Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma- associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis,” Molecular and Cellular Biology, vol. 17, no. 4, pp. 2312–2325, 1997. View at Google Scholar · View at Scopus
  82. P. K. Chan, “Cross-linkage of nucleophosmin in tumor cells by nitrogen mustard,” Cancer Research, vol. 49, no. 12, pp. 3271–3275, 1989. View at Google Scholar · View at Scopus
  83. B. Y. M. Yung and P. K. Chan, “Identification and characterization of a hexameric form of nucleolar phosphoprotein B23,” Biochimica et Biophysica Acta, vol. 925, no. 1, pp. 74–82, 1987. View at Google Scholar · View at Scopus
  84. H. Mano, “Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer,” Cancer Science, vol. 99, no. 12, pp. 2349–2355, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. A. Barreca, E. Lasorsa, L. Riera et al., “Anaplastic lymphoma kinase in human cancer,” Journal of Molecular Endocrinology, vol. 47, no. 1, pp. R11–R23, 2011. View at Publisher · View at Google Scholar · View at Scopus
  86. R. Chiarle, C. Voena, C. Ambrogio, R. Piva, and G. Inghirami, “The anaplastic lymphoma kinase in the pathogenesis of cancer,” Nature Reviews Cancer, vol. 8, no. 1, pp. 11–23, 2008. View at Publisher · View at Google Scholar · View at Scopus
  87. D. E. Levy and J. E. Darnell, “STATs: transcriptional control and biological impact,” Nature Reviews Molecular Cell Biology, vol. 3, no. 9, pp. 651–662, 2002. View at Publisher · View at Google Scholar · View at Scopus
  88. C. I. Santos and A. P. Costa-Pereira, “Signal transducers and activators of transcription-from cytokine signalling to cancer biology,” Biochimica et Biophysica Acta, vol. 1816, no. 1, pp. 38–49, 2011. View at Publisher · View at Google Scholar · View at Scopus
  89. Q. Zhang, P. N. Raghunath, L. Xue et al., “Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma,” Journal of Immunology, vol. 168, no. 1, pp. 466–474, 2002. View at Google Scholar · View at Scopus
  90. A. Zamo, R. Chiarle, R. Piva et al., “Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death,” Oncogene, vol. 21, no. 7, pp. 1038–1047, 2002. View at Publisher · View at Google Scholar · View at Scopus
  91. J. D. Khoury, L. J. Medeiros, G. Z. Rassidakis et al., “Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma,” Clinical Cancer Research, vol. 9, no. 10, part 1, pp. 3692–3699, 2003. View at Google Scholar · View at Scopus
  92. R. Chiarle, J. Z. Gong, I. Guasparri et al., “NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors,” Blood, vol. 101, no. 5, pp. 1919–1927, 2003. View at Publisher · View at Google Scholar · View at Scopus
  93. R. Chiarle, W. J. Simmons, H. Cai et al., “Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target,” Nature Medicine, vol. 11, no. 6, pp. 623–629, 2005. View at Publisher · View at Google Scholar · View at Scopus
  94. H. M. Amin, T. J. McDonnell, Y. Ma et al., “Selective inhibition of STAT3 induces apoptosis and G1 cell cycle arrest in ALK-positive anaplastic large cell lymphoma,” Oncogene, vol. 23, no. 32, pp. 5426–5434, 2004. View at Publisher · View at Google Scholar · View at Scopus
  95. R. Piva, L. Agnelli, E. Pellegrino et al., “Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms,” Journal of Clinical Oncology, vol. 28, no. 9, pp. 1583–1590, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. Q. Zhang, H. Wang, K. Kantekure et al., “Oncogenic tyrosine kinase NPM-ALK induces expression of the growth-promoting receptor ICOS,” Blood, vol. 118, no. 11, pp. 3062–3071, 2011. View at Google Scholar
  97. N. Anastasov, I. Bonzheim, M. Rudelius et al., “C/EBPβ expression in ALK-positiveanaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway,” Haematologica, vol. 95, no. 5, pp. 760–767, 2010. View at Publisher · View at Google Scholar · View at Scopus
  98. R. Piva, E. Pellegrino, M. Mattioli et al., “Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCl2A1 as critical target genes,” Journal of Clinical Investigation, vol. 116, no. 12, pp. 3171–3182, 2006. View at Publisher · View at Google Scholar · View at Scopus
  99. M. Marzec, Q. Zhang, A. Goradia et al., “Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1),” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 52, pp. 20852–20857, 2008. View at Publisher · View at Google Scholar · View at Scopus
  100. R. Yamamoto, M. Nishikori, M. Tashima et al., “B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma,” Cancer Science, vol. 100, no. 11, pp. 2093–2100, 2009. View at Publisher · View at Google Scholar · View at Scopus
  101. R. Lai, G. Z. Rassidakis, L. J. Medeiros et al., “Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma,” American Journal of Pathology, vol. 164, no. 6, pp. 2251–2258, 2004. View at Google Scholar · View at Scopus
  102. M. Marzec, X. Liu, W. Wong et al., “Oncogenic kinase NPM/ALK induces expression of HIF1α mRNA,” Oncogene, vol. 30, no. 11, pp. 1372–1378, 2011. View at Publisher · View at Google Scholar · View at Scopus
  103. J. Zhang, P. Wang, F. Wu et al., “Aberrant expression of the transcriptional factor Twist1 promotes invasiveness in ALK-positive anaplastic large cell lymphoma,” Cellular Signalling, vol. 24, no. 4, pp. 852–858, 2012. View at Google Scholar
  104. M. Kasprzycka, M. Marzec, X. Liu, Q. Zhang, and M. A. Wasik, “Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 26, pp. 9964–9969, 2006. View at Publisher · View at Google Scholar · View at Scopus
  105. C. Ambrogio, C. Martinengo, C. Voena et al., “NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells,” Cancer Research, vol. 69, no. 22, pp. 8611–8619, 2009. View at Publisher · View at Google Scholar · View at Scopus
  106. N. Sasai and P. A. Defossez, “Many paths to one goal? The proteins that recognize methylated DNA in eukaryotes,” The International Journal of Developmental Biology, vol. 53, no. 2-3, pp. 323–334, 2009. View at Publisher · View at Google Scholar · View at Scopus
  107. Q. Zhang, H. Y. Wang, X. Liu, G. Bhutani, K. Kantekure, and M. Wasik, “IL-2R common γ-chain is epigenetically silenced by nucleophosphin-anaplastic lymphoma kinase (NPM-ALK) and acts as a tumor suppressor by targeting NPM-ALK,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 29, pp. 11977–11982, 2011. View at Publisher · View at Google Scholar · View at Scopus
  108. Q. Zhang, H. Y. Wang, X. Liu, and M. A. Wasik, “STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression,” Nature Medicine, vol. 13, no. 11, pp. 1341–1348, 2007. View at Publisher · View at Google Scholar · View at Scopus
  109. D. K. Crockett, Z. Lin, K. S. J. Elenitoba-Johnson, and M. S. Lim, “Identification of NPM-ALK interacting proteins by tandem mass spectrometry,” Oncogene, vol. 23, no. 15, pp. 2617–2629, 2004. View at Publisher · View at Google Scholar · View at Scopus
  110. H. M. Amin, L. J. Medeiros, Y. Ma et al., “Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma,” Oncogene, vol. 22, no. 35, pp. 5399–5407, 2003. View at Publisher · View at Google Scholar · View at Scopus
  111. M. Marzec, M. Kasprzycka, A. Ptasznik et al., “Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3,” Laboratory Investigation, vol. 85, no. 12, pp. 1544–1554, 2005. View at Publisher · View at Google Scholar · View at Scopus
  112. J. D. Khoury, G. Z. Rassidakis, L. J. Medeiros, H. M. Amin, and R. Lai, “Methylation of SHP1 gene and loss of SHP1 protein expression are frequent in systemic anaplastic large cell lymphoma,” Blood, vol. 104, no. 5, pp. 1580–1581, 2004. View at Publisher · View at Google Scholar · View at Scopus
  113. Q. Zhang, H. Y. Wang, M. Marzec, P. N. Raghunath, T. Nagasawa, and M. A. Wasik, “STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 19, pp. 6948–6953, 2005. View at Publisher · View at Google Scholar · View at Scopus
  114. J. F. Honorat, A. Ragab, L. Lamant, G. Delsol, and J. Ragab-Thomas, “SHP1 tyrosine phosphatase negatively regulates NPM-ALK tyrosine kinase signaling,” Blood, vol. 107, no. 10, pp. 4130–4138, 2006. View at Publisher · View at Google Scholar · View at Scopus
  115. Y. Han, H. M. Amin, B. Franko, C. Frantz, X. Shi, and R. Lai, “Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma,” Blood, vol. 108, no. 8, pp. 2796–2803, 2006. View at Publisher · View at Google Scholar · View at Scopus
  116. Y. Han, H. M. Amin, C. Frantz et al., “Restoration of shp1 expression by 5-AZA-2′-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma,” Leukemia, vol. 20, no. 9, pp. 1602–1609, 2006. View at Publisher · View at Google Scholar · View at Scopus
  117. L. Qiu, R. Lai, Q. Lin et al., “Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells,” Blood, vol. 108, no. 7, pp. 2407–2415, 2006. View at Publisher · View at Google Scholar · View at Scopus
  118. J. D. Bard, P. Gelebart, M. Anand et al., “IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma,” American Journal of Pathology, vol. 175, no. 2, pp. 825–834, 2009. View at Publisher · View at Google Scholar · View at Scopus
  119. J. D. Bard, P. Gelebart, M. Anand, H. M. Amin, and R. Lai, “Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma,” Leukemia, vol. 22, no. 8, pp. 1595–1603, 2008. View at Publisher · View at Google Scholar · View at Scopus
  120. C. R. Geest and P. J. Coffer, “MAPK signaling pathways in the regulation of hematopoiesis,” Journal of Leukocyte Biology, vol. 86, no. 2, pp. 237–250, 2009. View at Publisher · View at Google Scholar · View at Scopus
  121. L. S. Steelman, R. A. Franklin, S. L. Abrams et al., “Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy,” Leukemia, vol. 25, no. 7, pp. 1080–1094, 2011. View at Publisher · View at Google Scholar · View at Scopus
  122. M. Watanabe, M. Sasaki, K. Itoh et al., “JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and Reed-Sternberg cells of Hodgkin lymphoma,” Cancer Research, vol. 65, no. 17, pp. 7628–7634, 2005. View at Publisher · View at Google Scholar · View at Scopus
  123. P. B. Staber, P. Vesely, N. Haq et al., “The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling,” Blood, vol. 110, no. 9, pp. 3374–3383, 2007. View at Publisher · View at Google Scholar · View at Scopus
  124. M. Marzec, M. Kasprzycka, X. Liu, P. N. Raghunath, P. Wlodarski, and M. A. Wasik, “Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf,” Oncogene, vol. 26, no. 6, pp. 813–821, 2007. View at Publisher · View at Google Scholar · View at Scopus
  125. M. S. Lim, M. L. Carlson, D. K. Crockett et al., “The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways,” Blood, vol. 114, no. 8, pp. 1585–1595, 2009. View at Publisher · View at Google Scholar · View at Scopus
  126. F. Vega, L. J. Medeiros, V. Leventaki et al., “Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma,” Cancer Research, vol. 66, no. 13, pp. 6589–6597, 2006. View at Publisher · View at Google Scholar · View at Scopus
  127. M. Marzec, M. Kasprzycka, X. Liu et al., “Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway,” Oncogene, vol. 26, no. 38, pp. 5606–5614, 2007. View at Publisher · View at Google Scholar · View at Scopus
  128. B. Magnuson, B. Ekim, D. C. Fingar et al., “Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks,” Biochemical Journal, vol. 441, no. 1, pp. 1–21, 2012. View at Google Scholar
  129. M. Fernandez, R. Manso, F. Bernaldez, P. Lopez, A. Martin-Duce, and S. Alemany, “Involvement of Cot activity in the proliferation of ALCL lymphoma cells,” Biochemical and Biophysical Research Communications, vol. 411, no. 4, pp. 655–660, 2011. View at Google Scholar
  130. B. D. Manning and L. C. Cantley, “Rheb fills a GAP between TSC and TOR,” Trends in Biochemical Sciences, vol. 28, no. 11, pp. 573–576, 2003. View at Publisher · View at Google Scholar · View at Scopus
  131. X. M. Ma and J. Blenis, “Molecular mechanisms of mTOR-mediated translational control,” Nature Reviews Molecular Cell Biology, vol. 10, no. 5, pp. 307–318, 2009. View at Publisher · View at Google Scholar · View at Scopus
  132. O. Merkel, F. Hamacher, D. Laimer et al., “Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 37, pp. 16228–16233, 2010. View at Publisher · View at Google Scholar · View at Scopus
  133. M. Watanabe, K. Itoh, T. Togano, M. E. Kadin, T. Watanabe, and R. Horie, “Ets-1 activates overexpression of JunB and CD30 in Hodgkin's lymphoma and anaplastic large-cell lymphoma,” The American Journal of Pathology, vol. 180, no. 2, pp. 831–838, 2012. View at Google Scholar · View at Scopus
  134. S. Mathas, M. Hinz, I. Anagnostopoulos et al., “Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-κB,” The EMBO Journal, vol. 21, no. 15, pp. 4104–4113, 2002. View at Publisher · View at Google Scholar · View at Scopus
  135. A. P. Szremska, L. Kenner, E. Weisz et al., “JunB inhibits proliferation and transformation in B-lymphoid cells,” Blood, vol. 102, no. 12, pp. 4159–4165, 2003. View at Publisher · View at Google Scholar · View at Scopus
  136. G. Z. Rassidakis, A. Thomaides, C. Atwell et al., “JunB expression is a common feature of CD30+ lymphomas and lymphomatoid papulosis,” Modern Pathology, vol. 18, no. 10, pp. 1365–1370, 2005. View at Publisher · View at Google Scholar · View at Scopus
  137. F. Y. Y. Hsu, P. B. Johnston, K. A. Burke, and Y. Zhao, “The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner,” Cancer Research, vol. 66, no. 18, pp. 9002–9008, 2006. View at Publisher · View at Google Scholar · View at Scopus
  138. J. D. Pearson, J. K. Lee, J. T. Bacani, R. Lai, and R. J. Ingham, “NPM-ALK and the JunB transcription factor regulate the expression of cytotoxic molecules in ALK-positive, anaplastic large cell lymphoma,” International Journal of Clinical and Experimental Pathology, vol. 4, no. 2, pp. 124–133, 2011. View at Google Scholar · View at Scopus
  139. J. G. Christensen, H. Y. Zou, M. E. Arango et al., “Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma,” Molecular Cancer Therapeutics, vol. 6, no. 12, pp. 3314–3322, 2007. View at Publisher · View at Google Scholar · View at Scopus
  140. U. Ritter, C. Damm-Welk, U. Fuchs, R. M. Bohle, A. Borkhardt, and W. Woessmann, “Design and evaluation of chemically synthesized siRNA targeting the NPM-ALK fusion site in anaplastic large cell lymphoma (ALCL),” Oligonucleotides, vol. 13, no. 5, pp. 365–373, 2003. View at Publisher · View at Google Scholar · View at Scopus
  141. S. D. Turner, D. Yeung, K. Hadfield, S. J. Cook, and D. R. Alexander, “The NPM-ALK tyrosine kinase mimics TCR signalling pathways, inducing NFAT and AP-1 by RAS-dependent mechanisms,” Cellular Signalling, vol. 19, no. 4, pp. 740–747, 2007. View at Publisher · View at Google Scholar · View at Scopus
  142. C. Voena, C. Conte, C. Ambrogio et al., “The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration,” Cancer Research, vol. 67, no. 9, pp. 4278–4286, 2007. View at Publisher · View at Google Scholar · View at Scopus
  143. L. Riera, E. Lasorsa, C. Ambrogio, N. Surrenti, C. Voena, and R. Chiarle, “Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth,” Journal of Biological Chemistry, vol. 285, no. 34, pp. 26441–26450, 2010. View at Publisher · View at Google Scholar · View at Scopus
  144. L. C. Cantley, “The phosphoinositide 3-kinase pathway,” Science, vol. 296, no. 5573, pp. 1655–1657, 2002. View at Publisher · View at Google Scholar · View at Scopus
  145. P. Liu, H. Cheng, T. M. Roberts, and J. J. Zhao, “Targeting the phosphoinositide 3-kinase pathway in cancer,” Nature Reviews Drug Discovery, vol. 8, no. 8, pp. 627–644, 2009. View at Publisher · View at Google Scholar · View at Scopus
  146. R. Y. Bai, T. Ouyang, C. Miething, S. W. Morris, C. Peschel, and J. Duyster, “Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway,” Blood, vol. 96, no. 13, pp. 4319–4327, 2000. View at Google Scholar · View at Scopus
  147. A. Slupianek, M. Nieborowska-Skorska, G. Hoser et al., “Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis,” Cancer Research, vol. 61, no. 5, pp. 2194–2199, 2001. View at Google Scholar · View at Scopus
  148. D. A. E. Cross, D. R. Alessi, P. Cohen, M. Andjelkovich, and B. A. Hemmings, “Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B,” Nature, vol. 378, no. 6559, pp. 785–789, 1995. View at Publisher · View at Google Scholar · View at Scopus
  149. S. R. McDonnell, S. R. Hwang, V. Basrur et al., “NPM-ALK signals through glycogen synthase kinase 3beta to promote oncogenesis,” Oncogene. In press.
  150. A. Fernandez-Vidal, A. Mazars, E. F. Gautier, G. Prévost, B. Payrastre, and S. Manenti, “Upregulation of the CDC25A phosphatase down-stream of the NPM/ALK oncogene participates to anaplastic large cell lymphoma enhanced proliferation,” Cell Cycle, vol. 8, no. 9, pp. 1373–1379, 2009. View at Google Scholar · View at Scopus
  151. R. R. Singh, J. H. Cho-Vega, Y. Davuluri et al., “Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma,” Cancer Research, vol. 69, no. 6, pp. 2550–2558, 2009. View at Publisher · View at Google Scholar · View at Scopus
  152. H. Zhu and H. W. Lo, “The human glioma-associated oncogene homolog 1 (GLI1) family of transcription factors in gene regulation and diseases,” Current Genomics, vol. 11, no. 4, pp. 238–245, 2010. View at Publisher · View at Google Scholar · View at Scopus
  153. T. L. Gu, Z. Tothova, B. Scheijen, J. D. Griffin, D. G. Gilliland, and D. W. Sternberg, “NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a,” Blood, vol. 103, no. 12, pp. 4622–4629, 2004. View at Publisher · View at Google Scholar · View at Scopus
  154. H. Huang and D. J. Tindall, “Dynamic FoxO transcription factors,” Journal of Cell Science, vol. 120, no. 15, pp. 2479–2487, 2007. View at Publisher · View at Google Scholar · View at Scopus
  155. P. F. Dijkers, R. H. Medema, J. W. J. Lammers, L. Koenderman, and P. J. Coffer, “Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1,” Current Biology, vol. 10, no. 19, pp. 1201–1204, 2000. View at Publisher · View at Google Scholar · View at Scopus
  156. P. F. Dijkers, R. H. Medema, C. Pals et al., “Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27KIP1,” Molecular and Cellular Biology, vol. 20, no. 24, pp. 9138–9148, 2000. View at Publisher · View at Google Scholar · View at Scopus
  157. A. Slupianek and T. Skorski, “NPM/ALK downregulates p27KIP1 in a PI-3K-dependent manner,” Experimental Hematology, vol. 32, no. 12, pp. 1265–1271, 2004. View at Publisher · View at Google Scholar · View at Scopus
  158. G. Z. Rassidakis, M. Feretzaki, C. Atwell et al., “Inhibition of Akt increases p27KIP1 levels and induces cell cycle arrest in anaplastic large cell lymphoma,” Blood, vol. 105, no. 2, pp. 827–829, 2005. View at Publisher · View at Google Scholar · View at Scopus
  159. D. Polgar, C. Leisser, S. Maier et al., “Truncated ALK derived from chromosomal translocation t(2;5)(p23;q35) binds to the SH3 domain of p85-PI3K,” Mutation Research, vol. 570, no. 1, pp. 9–15, 2005. View at Publisher · View at Google Scholar · View at Scopus
  160. W. Wan, M. S. Albom, L. Lu et al., “Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells,” Blood, vol. 107, no. 4, pp. 1617–1623, 2006. View at Publisher · View at Google Scholar · View at Scopus
  161. A. H. Uner, A. Saglam, U. Han, M. Hayran, A. Sungur, and S. Ruacan, “PTEN and p27 expression in mature T-cell and NK-cell neoplasms,” Leukemia and Lymphoma, vol. 46, no. 10, pp. 1463–1470, 2005. View at Publisher · View at Google Scholar · View at Scopus
  162. S. Momose, J. I. Tamaru, H. Kishi et al., “Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion,” Human Pathology, vol. 40, no. 1, pp. 75–82, 2009. View at Publisher · View at Google Scholar · View at Scopus
  163. Z. Chen, T. Sasaki, X. Tan et al., “Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene,” Cancer Research, vol. 70, no. 23, pp. 9827–9836, 2010. View at Publisher · View at Google Scholar · View at Scopus
  164. Y. Li, X. Ye, J. Liu, J. Zha, and L. Pei, “Evaluation of eml4-alk fusion proteins in non-small cell lung cancer using small molecule inhibitors,” Neoplasia, vol. 13, no. 1, pp. 1–11, 2011. View at Publisher · View at Google Scholar · View at Scopus
  165. K. Takezawa, I. Okamoto, K. Nishio, P. A. Jänne, and K. Nakagawa, “Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer,” Clinical Cancer Research, vol. 17, no. 8, pp. 2140–2148, 2011. View at Publisher · View at Google Scholar · View at Scopus
  166. F. Armstrong, M. M. Duplantier, P. Trempat et al., “Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells,” Oncogene, vol. 23, no. 36, pp. 6071–6082, 2004. View at Publisher · View at Google Scholar · View at Scopus
  167. S. D. Bohling, S. D. Jenson, D. K. Crockett, J. A. Schumacher, K. S. J. Elenitoba-Johnson, and M. S. Lim, “Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma,” Leukemia Research, vol. 32, no. 3, pp. 383–393, 2008. View at Publisher · View at Google Scholar · View at Scopus